Table 3.

Complete prevalence (CP)^a and proportion (%) of patients who reached different levels of conditional relative survival (CRS)^b by cancer type and sex. Italy 1985–2005

Cancer type, ICD10	Men				Women
	CP	Five-year CRS	Five-year CRS	Ten-year CRS	CP	Five-year CRS	Five-year CRS	Ten-year CRS
	×100 000	>90%	>95%	>95%	×100 000	>90%	>95%	>95%
Oral cavity, C01–14	99	30%	23%	22%	49	43%	35%	32%
Oesophagus, C15	13	18%	15%	15%	4	29%	26%	26%
Stomach, C16	109	47%	38%	37%	73	58%	49%	47%
Colon and rectum, C18–21	422	41%	30%	27%	352	52%	40%	36%
Liver, C22	46	1%	1%	1%	16	9%	8%	7%
Gallbladder, C23–24	10	20%	14%	13%	12	26%	20%	20%
Pancreas, C25	17	18%	16%	16%	13	22%	19%	19%
Larynx, C32	141	15%	0%	0%	14	14%	0%	0%
Lung, C33–34	174	23%	18%	17%	60	21%	17%	15%
Skin melanoma, C43	140	54%	38%	36%	184	76%	49%	41%
Connective tissue, C47, C49	42	67%	58%	55%	35	70%	59%	55%
Breast, C50					1709	41%	12%	6%
Vagina and vulva, C51–52					19	40%	25%	18%
Cervix uteri, C53					167	82%	75%	73%
Corpus uteri, C54					258	71%	56%	50%
Ovary, C56					136	51%	43%	42%
Prostate, C61	592	4%	0%	0%
Testis, C62	150	95%	94%	93%
Kidney, C64–66, C68	181	39%	12%	2%	97	57%	36%	26%
Bladder, C67, D09.0, D30.3, D41.4	438	29%	5%	1%	98	58%	25%	10%
Brain, C70–72	57	58%	54%	53%	56	67%	63%	63%
Thyroid, C73	74	74%	58%	54%	255	87%	78%	78%
Hodgkin lymphoma, C81	95	85%	65%	59%	78	88%	68%	52%
Non-Hodgkin lymphoma, C82–85, C96	176	31%	14%	4%	159	34%	7%	1%
Multiple myeloma, C88–90	35	2%	1%	0%	29	2%	1%	0%
Leukaemia, C91–95	87	7%	0%	0%	69	13%	0%	0%

^aAt 1 January 2006 in patients aged 15–74 years living after a cancer diagnosis, calculated as a sum of age-specific estimates of prevalence.

^bEstimates are based on the relative survival function for each type and sex parameterized using mixture cure models.